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Recombinant human GH has been licensed for use in adult patients with GH deficiency (GHD) for over
15 years. Early weight- and surface area-based dosing regimens were effective but resulted in
supraphysiological levels of IGF1 and increased incidence of side effects. Current practice has moved
towards individualised regimens, starting with low GH doses and gradually titrating the dose
according to the level of serum IGF1 to achieve an optimal dose. Here we present the evidence
supporting the dosing recommendations of current guidelines and consider factors affecting dose
responsiveness and parameters of treatment response. The published data discussed here lend support
for the use of low GH dosing regimens in adult GHD. The range of doses defined as ‘low dose’ in the
studies discussed here (w1–4 mg/week) is in accordance with those recommended in current
guidelines and encompasses the dose range recommended by product labels.
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The goal of GH replacement therapy for children with GH
deficiency (GHD) is normalisation of height during
childhood and attainment of normal adult height.
However, even after final height is achieved, there is
evidence that GH is still required, and it is generally
accepted that it may be beneficial to continue GH therapy
beyond final height in order to achieve peak bone mass,
muscle mass, and strength (1). Negative consequences
associated with cessation of therapy, such as reduced
psychological well-being, adverse changes in lipid profile
and changes in body composition, suggest that for some
patients there may be ongoing GHD. After retesting to
confirm a diagnosis of GHD, continuation of therapy is
necessary for maintenance of normal body composition,
metabolic processes, and psychological functioning.
In adults, GH is important for supporting various
physiological and metabolic processes, and those who
develop GHD in adulthood (e.g. acquired from damage to
the pituitary gland or hypothalamus) can have a wide
variety of morphological, metabolic, physical, and
psychological problems (2, 3, 4). These include increased
fat mass and visceral adiposity, abnormally low lean
body mass, higher-than-normal blood total cholesterol
(TC) and LDL-C and triglycerides, and lower than
normal HDL-C, reduced muscle strength and exercisendocrinologyperformance, low bone mineral content leading to
osteoporosis and increased fracture risk, increased
cardiovascular morbidity and mortality, an impaired
sense of well-being, decreased energy levels and a general
reduction in quality of life (QoL).
Treatment goals for adults with GHD are to correct
the clinical alterations described above, using insulin-
like growth factor 1 (IGF1) levels as a marker of
treatment, in order to achieve or maintain IGF1 levels in
the middle of the normal range appropriate for age and
sex, with an optimal level of physical and psychosocial
function (5, 6, 7). GH dosing in adult GHD (AGHD) was
initially adopted from paediatric practice and was
subsequently found to cause supraphysiological levels
of IGF1 and to cause increased levels of common side
effects such as arthralgia and peripheral oedema (8).
Following these early attempts to correct AGHD,
dosing plans have evolved, and a number of guidelines
relating to treatment initiation, titration, and moni-
toring have been published (Table 1) (4, 5, 7). Rather
than the weight- and surface area-based dosing
strategies used initially with important side effects
related to arthralgia and peripheral oedema (7),
treatment regimens now use tailored dose-titration
strategies to account for inter-individual differences in
GH sensitivity (which are dependent on age, gender and
various baseline characteristics), with lower doses thanDOI: 10.1530/EJE-12-0563
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Table 1 Current guidelines on the use of GH in adult patients with GHD.
Endocrine Society (4) Recommend that GH-dosing regimens be individualised, rather than weight-based
Recommend start with low doses and titrate according to clinical response, side effects and IGF1 levels
Recommend that dosing take gender, oestrogen status, and age into consideration
Suggest that during treatment, patients be monitored at 1–2-month intervals during dose titration and semi-annually thereafter
with a clinical assessment and an evaluation for adverse events, IGF1 levels and other parameters of GH response
American Association
of Clinical
Endocrinologists
(AACE) (5)
Starting dose
Age !30 years, 0.4–0.5 mg/day (may be higher for patients transitioning from paediatric treatment)
Age 30–60 years, 0.2–0.3 mg/day
Age O60 years, 0.1–0.2 mg/day
Use lower GH doses (0.1–0.2 mg/day) in all patients with diabetes or who are susceptible to glucose intolerance
At 1–2-month intervals, increase dose in increments of 0.1–0.2 mg/day based on clinical response, serum IGF1 levels, side
effects and individual considerations such as glucose intolerance. Longer time intervals and smaller dose increments may be
necessary in older patients
Aim for serum IGF1 levels in the middle of the normal range appropriate for age and sex, unless side effects are significant.
Consider a trial of higher GH doses to determine whether this provides further benefit as long as the serum IGF1 levels
remain within the normal range and the patient does not experience side effects
Monitor at 6-month intervals once maintenance doses are achieved. Monitoring should include clinical evaluation and
assessment of side effects, serum IGF1 and fasting glucose levels. The lipid profile should be assessed annually, and QoL
measurements may be done every 6 or 12 months. If the initial bone DXA scan is abnormal, repeat evaluations at 2–3-year
intervals are recommended. If pituitary microadenomas or post-surgery residual pituitary tumour is still present, periodic
MRIs should be undertaken. Patients on concurrent thyroid, glucocorticoid and gonadal hormone replacement may need
dose adjustments after starting GH replacement therapy
It is important to retest patients transitioning from paediatric to adult care, especially those who had isolated GHD, and
consideration should be given to minimising lengthy interruptions in their GH therapy
The appropriate length of GH therapy is unclear. If benefits are achieved, treatment should continue, but if no apparent or
objective benefits of treatment are achieved after at least 2 years, discontinuing GH therapy may be considered. If patients
decide to discontinue GH replacement therapy, a 6-month follow-up appointment should be offered, because a substantial
number of patients may wish to resume therapy, noting in retrospect that they did feel better on treatment
Growth Hormone
Research Society
(GRS) (6)
Recommended that the starting dose in young men and women be 0.2 and 0.3 mg/day respectively, and in older individuals,
0.1 mg/day. Dose determination based on body weight is not recommended due to large inter-individual variation in
absorption and in sensitivity to GH, and the lack of evidence that a larger replacement dose is required for heavier individuals
in adults
Dose escalation should be gradual, individualised, and guided by clinical and biochemical response
In elderly patients with GHD, treatment can be achieved with lower doses, concordant with the observed physiological
decrease in GH secretion. Elderly patients are known to be more sensitive to GH and prone to side effects; therefore, the
dose should be adjusted carefully
A careful clinical exam should be undertaken with weight, height, and BMI recorded before commencing therapy. Objective
parameters such as body composition should be used to monitor the response
IGF1 should be measured at least yearly and should be maintained below the age- and gender-related upper limit of normal. In the
event of dose adjustment, assessment should be performed no sooner than 6 weeks after a dose change
Cardiovascular risk markers and fasting glucose levels should be measured yearly
A careful history of QoL with attention to energy level, partner satisfaction, sick days and vitality is of value in monitoring
treatment response
DXA, dual-energy X-ray absorptiometry; GHD, GH deficiency; IGF, insulin-like growth factor; MRI, magnetic resonance imaging; QoL, quality of life.
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recommend that, during initial therapy, patients are
monitored monthly and the GH dose is titrated to reach
target IGF1 levels (5). Once maintenance doses are
reached, patients should be monitored every 6–12
months, with a clinical assessment and an evaluation
for adverse effects, level of serum IGF1 and other
parameters of GH response, such as body composition,
cardiovascular risk factors and QoL.
Clinical studies drive published guidelines, which, in
turn, inform product labelling. In European countries,
current label information for the major brands of
recombinant human GH on the market recommends
starting doses of about 0.15–0.30 mg/day in adult
patients (0.20–0.50 mg/day for those with childhood-
onset (CO) GHD) and seldom exceed 1 mg/day (9, 10,
11, 12, 13). In the USA, non-weight-based (generally,www.eje-online.org0.15–0.30 mg/day) and weight-based (generally,
%0.006 mg/kg per day) dosing recommendations are
provided in product labels (14, 15, 16, 17, 18).
Here we undertook a systematic approach to gather
evidence in support of current recommendations on GH
therapy for adult patients with GHD (4, 5, 7). We reviewed
the studies that explore GH dosing schedules, titration
strategies and factors affecting responsiveness to GH, and
discuss different approaches to treatment monitoring.Literature selection methodology
Searches for relevant publications were carried out in
PubMed using the search terms growth hormone
deficiency AND growth hormone plus one of the
following terms: (‘start* dose’ OR ‘start* dosage’) and
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were limited to human studies published in English
between January 1990 and March 2011. Following the
removal of duplicates, abstracts were assessed for
suitability for inclusion in the review. Abstracts that
were judged relevant for the main scope of the work
were selected; the studies selected were those judged to
represent the ‘best evidence’ (i.e. were of a given level of
scientific substantiation or proof) such as large,
prospective, randomised, controlled trials; observational
studies and experimental studies (5): additional papers
that provided useful background information and/or
insightful comment were also included. Full-text articles
of suitable abstracts were then screened to select articles
of relevance. Search results were supplemented with
additional references of interest as identified by the
authors (Fig. 1). References that explore GH starting
dose and lower-dose regimens are listed in Table 2.GH dosing schedules and titration
strategies
The response to GH therapy in adults is variable. A
dosing schedule that is suboptimal in one patient may
lead to overdose in another, and normalisation of serum
IGF1 can induce side effects in some. Therefore, it is
recommended that each patient’s GH dosing regimen
should be titrated to balance clinical efficacy against
overtreatment, as determined by serum IGF1 measure-
ments and the occurrence of side effects (19).
Practical guidance for GH dosing was developed over
10 years ago. Starting doses ofO300 mg/day were not
recommended. Dosing was guided by serum IGF1
concentrations (monitored every 6–8 weeks until levels
of IGF1 were in the mid-to-high normal range for ageRecords identified through
database searching
(n = 524)
Records after duplicates removed
(n = 451)
Records screened
(n = 451)
Full-text articles assessed
for eligibility
(n = 114)
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qualitative synthesis
(n = 43)
Additional records identified
through other sources*
(n = 14)and sex) and tolerability. If musculoskeletal pain, carpal
tunnel symptoms, or aggravation of hypertension
appeared within the first 10 days of initiation of therapy
or a dose increment, which then resolved within
2 weeks, it was recommended that patients remain on
that dose; dose reductions were recommended for
symptoms that persisted beyond 2 weeks. Two or
three dose changes may be required before a satisfactory
dose is defined. Additionally, patients should be advised
that complete resolution of the side effects may require
1–2 months (2, 3, 4, 20, 21).
Although IGF1 is recognised as the most useful serum
marker for GH dose titration in adults, the American
Association of Clinical Endocrinologists (AACE) guide-
lines (5) acknowledge that no data are available
regarding titrating the dose to the ideal target serum
IGF1 level (i.e. whether to target the middle or the upper
half (O50th percentile or O0 SDS of the reference
range for maximum benefit). The AACE therefore
recommend targeting IGF1 to the middle of the age-
and sex-appropriate reference range quoted by the
laboratory used (50th percentile or 0 SDS), unless side
effects are significant; a trial of a higher dose may be
considered to determine whether this provides further
benefit, provided that the levels of IGF1 remain within
the normal range and that the patient does not
experience side effects.
Clinical studies use slightly different IGF1 targets
within the reference range, although all have demon-
strated the clinical efficacy of their particular GH
replacement therapy regimen in adult patients.
Ahmad et al. (22) maintained IGF1 concentrations
between the median and upper end of the age-related
reference range, while Pincelli et al. (23) aimed to
restore IGF1 concentrations to the low-normal sex- and
age-related reference range. The regimen used in thet articles excluded
(n = 71)
ords excluded
(n = 337)
Figure 1 Literature identification. *Based on
the expertise of the authors or suggestions
during the peer review process.
www.eje-online.org
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between K2 and C2 S.D. of the age-related normal
range. A review article by Alexopolou et al. (25)
concluded that the objective of AGHD therapy is toTable 2 Studies included in the review. Studies listed here are origina
GH starting dose and lower-dose regimens.
Authors
Year of
publication
Case
load (n) Age
Durat
of stu
Ahmad
et al. (22)
2001 46 Mean, 50.4 years;
range, 26–72 years
3 Mon
Amato
et al. (34)
1996 9 Range, 25–34 years 24 Mo
Hoffman
et al. (29)
2004 387 Mean, 48.1G13.3;
45.1G14.1
32 We
Johannsson
et al. (28)
1997 60 Mean, 48 years;
range, 18–67 years
12 Mo
Møller
et al. (30)
1993 10 Range, 21–43 years 12 We
Mukherjee
et al. (45)
2005 30 Range, 17–65 years 6 Mon
Murray
et al. (24)
1999 65 Mean, 38.7 years;
range, 17–72 years
w9.5
ma
dos
Murray
et al. (35)
2002 67 Mean, 37.5G14.7
years
24 Mo
Orme
et al. (33)
1992 8 Mean, 50 years;
range, 22–75 years
8 Wee
Porretti
et al. (54)
2002 66 Mean, 39G16 years,
range, 18–71 years
6 Mon
Verhelst
et al. (27)
1997 148 Mean, 43.8 years 2 Yea
Yuen
et al. (31)
2002 13 Range, 23–63 years Four 7
pha
10-
was
eac
Yuen
et al. (51)
2006 26 Range, 20–63 years 8 Wee
IGF1, insulin-like growth factor 1.
www.eje-online.orgobtain an IGF1 level in the upper half of the normal
range for age and gender, ideally between the median
and C1 S.D., although some advocate values between
C1 and C2 sS.D. Johansson et al. (19), as part of thel studies identified in the literature selection that specifically explore
ion
dy Dose/regimen used
ths Initiated at 0.4–0.5 IU/day and titrated to achieve
IGF1 SDS between median and upper end of
age-related reference range
nths 70 mg/kg per week for 12 months
eks Fixed-dose group: subjects received sequentially
4 (4 months), 8 (2 months), and 12 (2 months)
mg/kg per day GH. Individualised-dose group:
started at 0.2 mg/day (2 months) and
increased by 0.2 mg/day increments at
2-month intervals, based on clinical and serum
IGF1 responses, to a maximum of 0.8 mg/day
nths High-dose group: daily dose of 4.8 mg/kg
(0.1 IU/kg per week) during first 4 weeks, with
a target dose thereafter of 12 mg/kg per day
(0.25 IU/kg per week). Individualised-dose
group: initial daily dose 0.17 mg (0.5 IU) or
0.33 mg (1.0 IU)/day, independent of body
weight, with dose adjustments thereafter
eks 1, 2, and 4 IU/m2 per day (three consecutive
4-week study periods)
ths Patients started on 0.3 mg/day and dose
adjusted as necessary
Months at
intenance
e
Treatment initiated at 0.8 U/day and sub-
sequently adjusted by increments of 0.4 U/day
to normalise the IGF1 SDS betweenK2.0 and
C2.0 S.D. of the age-related normal range
nths GH was commenced at a dose of 0.27 mg/day
and was subsequently adjusted at intervals of
4–6 weeks to normalise the serum IGF1 within
the range ofC2 toK2 S.D. of the age-adjusted
mean in the absence of GH-related side effects
ks 4 U three times per week, for 8 weeks
ths Low-dose regimen, 3 mg/kg per day for 3 months
followed by 6 mg/kg per day for another
3 months
Higher dose regimen, 6 mg/kg per day for
3 months followed by 12 mg/kg per day for
another 3 months
rs During month 1, 0.125 IU/kg per week, followed
by 0.25 IU/kg per week for next 5 months
(maximum dose 4 IU/day). The open period
(additional 18 months) commenced with a
dose of 0.125 IU/kg per week for 1 month and
then 0.25 IU/kg per week (w1.5 IU/m2 per
day). Dose adjustments were made in case of
adverse effects or when deemed appropriate
by the investigators
-day treatment
ses, with a
day to 2-week
hout in between
h phase
7-Day treatment course of two ‘physiological’
(‘lowest’ dose, 0.0017 mg/kg per day; ‘low’
dose, 0.0033 g/kg per day) vs two ‘supraphy-
siological’ (‘high’ dose, 0.010 mg/kg per day;
‘highest’ dose, 0.025 mg/kg per day) GH
doses
ks Fixed regimen of non-weight-based low-dose
GH replacement (0.2 mg/day) for 8 weeks
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Workshop held in 2007, reported that it was agreed
that most published trials showing beneficial effects of
GH have achieved a mean serum IGF1 level ofC1 SDS,
but for the individual patient, determination of the level
of IGF1 SDS to be obtained should be guided by other
biochemical response markers and the clinical response.
Adult patients with GHD but normal IGF1 levels
remain a therapeutic challenge, as there are few data to
help understand whether they benefit from GH therapy
and how to monitor therapy in the clinical setting.Weight-based vs individualised regimens
Current guidelines acknowledge that high inter-indi-
vidual variability in both GH absorption and sensitivity
makes the individualised, stepwise, upward titration
method preferable to standard weight-based dosing
strategies (5, 7, 26). The finding of suboptimal high or
low levels of serum IGF1 in O60% of patients in a
2-year study of GH replacement therapy in adults with
GHD given a weight-dependent dose reinforces the
guidelines and emphasises that the dose should be
titrated individually for each patient by monitoring
levels of IGF1 (27).
Head-to-head comparisons of individualised and
weight-based dosing strategies provide evidence that
individualised-dose (ID) titration leads to similar
beneficial effects and fewer side effects than weight-
based regimens. In the study of Johannsson et al. (28),
two groups of patients were treated for 12 months using
one of two schedules. The high-dose (HD) group (nZ30)
received a conventional weight-based regimen of
4.8 mg/kg per day (0.1 IU/kg per week) during the
first 4 weeks, with a target dose of 12 mg/kg per day
(0.25 IU/kg per week) thereafter; the ID group (nZ30)
received initial doses of either 0.17 or 0.33 mg/day (0.5
and 1 IU/day respectively), independent of body weight,
with ID adjustments made thereafter to match a
combination of clinical response, normalisation of
serum IGF1 concentration and body composition.
After 12 months, the daily GH dose was 0.55G0.03
and 0.45G0.03 mg in the HD and ID groups
respectively (P!0.05). In the HD group, mean IGF1
level increased to well above the predicted level, while in
the ID group, the mean IGF1 normalised. Side effects
were experienced by 70% of the HD group and 30% of
the ID group (P!0.001). A similar response was
observed in both groups in terms of changes in body
composition, glucose homoeostasis, lipoprotein levels
and blood pressure, although dose dependency was
observed for the response in markers reflecting calcium
and bone metabolism. Overall, the study concluded that
similar efficacy, with lower dose and fewer side effects,
was obtained by considering individual responsiveness
to GH compared with higher doses adjusted to match
body weight. This conclusion was supported by a large,multicentre, randomised controlled study (29) in which
387 adults with GHD were randomised to receive either
a fixed dose (FD; nZ200) or an ID (nZ187) of GH for
32 weeks. Subjects in the FD arm began therapy at a
dose of 4.0 mg/kg per day for 4 months, increasing to
8.0 mg/kg per day for 2 months, followed by 12.0 mg/kg
per day for the final 2 months of the study. Patients in
the ID arm received an initial dose of 200 mg/day, which
was increased by 200 mg/day at 2-month intervals,
according to an algorithm based on the clinical response
and serum IGF1 concentrations, to a maximum dose of
800 mg/day. Data indicated that individualised dosing
had similar clinical efficacy but improved tolerability,
compared with the fixed, weight-based regimen, with
lower occurrence of peripheral oedema (9.1 vs 16.5%,
PZ0.03) and rash (1.1 vs 5.5%, PZ0.02) in the ID vs
the FD arm.
Studies directly comparing different doses of GH
support the use of lower starting doses. Møller et al.
(30) examined the effects of different doses of GH on
IGF1, IGF-binding protein 3 (IGFBP3), body compo-
sition, energy expenditure and various metabolites in
ten adult patients (20–45 years of age) with GHD, who
were studied after 4 weeks without GH followed by three
consecutive 4-week periods during which they received
1, 2, and 4 IU/m2 per day (0.33, 0.67, and 1.33 mg/m2
per day respectively) GH. The use of 1 and 2 IU/m2 per
day GH was associated with normalisation of IGF1
levels, whereas the higher dose of 4 IU/m2 per day
caused distinct side effects in four of the ten patients and
yielded supranormal levels of IGF1 compared with a
matched control group. The authors concluded that a
replacement dose of 1–2 IU/m2 per day was relevant
and expedient in adults with GHD between 20 and 45
years of age. Yuen et al. (31) compared the metabolic
effects of short-term administration of two doses
representing a close approximation to daily physiologi-
cal GH production rates in adults (‘lowest’ dose,
0.0017 mg/kg per day; ‘low’ dose, 0.0033 mg/kg per
day) with two ‘supraphysiological’ (‘high’ dose,
0.010 mg/kg per day; ‘highest’ dose, 0.025 mg/kg per
day) GH doses. Results suggested that short-term
administration of the highest GH dose induced insulin
resistance, whereas the low and lowest GH doses did not
compromise insulin sensitivity. Interestingly, an
increase in b-cell function was observed with the lowest
dose, suggesting that this dose had direct insulino-
trophic effects on b-cells. The authors concluded that
their findings were in agreement with the recommen-
dations of the GRS (32) to commence treatment with
low GH doses, and that their lowest dose could be the
optimal starting dose, as it seemed to provide the
additional benefit of enhancing b-cell function, at least
initially, without compromising insulin sensitivity.
A number of studies using low-dose regimens to treat
adults with GHD (most of which were individualised by
upward titration against serum IGF1 levels) have
achieved good efficacy and safety outcomes, providingwww.eje-online.org
AUTHOR COPY ONLY
R60 V Gasco and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168support for such dosing strategies. Orme et al. (33)
assessed the effects of low-dose GH in eight adults with
GHD on body composition and physical performance.
Patients received 4 IU (1.33 mg) GH, three times per
week (tiw) for an 8-week period. Although a lower than
previously used mean dose of GH (0.025 IU/kg per day)
was given, and the frequency of administration was also
less than generally used, biological effects were seen in
this patient group. This finding showed that a low dose
of GH could increase IGF1 levels and have a pronounced
physical effect in the GH-deficient adult (an increase in
exercise capacity and in fat-free mass, and a decline in
fat mass), without the side effects observed at higher
dosage schedules. In the study by Amato et al. (34), the
lowest dose so far used in trials focusing on bone
metabolism and structure in AGHD was used in a dosing
regimen of 70 mg/kg per week divided into three
injections. Results suggested that 12 months of low-
dose GH therapy normalised bone metabolism and
cortical bone density, and improved trabecular bone
density without causing adverse events. The effects of
low-dose GH replacement on body composition and QoL
were studied by Ahmad et al. (22). A starting daily dose
of 0.4–0.5 IU (0.13–0.17 mg) that was titrated to
achieve and maintain IGF1 SDS between the median
and upper end of the age-related reference range (mean
GH dose of 0.77G0.08 IU at 1 month and 0.80
G0.12 IU at 3 months) was associated with an
improvement in body composition and QoL. These
changes were apparent as early as 1 month after
initiation of treatment, with beneficial effects continu-
ing at 3 months, an earlier effect than reported
previously on such outcomes with either high- or low-
dose therapy. Importantly, these changes occurred in
the absence of side effects.
Murray et al. (35) explored whether the beneficial
effects on serum lipids found when using weight-based
GH replacement regimens were retained with low-dose,
individually optimised regimens, and which patient
characteristics best predicted outcome. GH was com-
menced at 0.27 mg/day, and the dose was subsequently
adjusted, with the objective of normalising levels of
serum IGF1. This dosing regimen was associated with
significant improvements in TC, LDL-C, triglycerides,
and the TC/HDL-C ratio. The effects on cardiovascular
and heart parameters of a 1-year low-dose titrated, tiw
GH-replacement regimen, aimed at achieving and
maintaining IGF1 levels within the low-normal limits
for age and sex, were studied by Pincelli et al. (23) in a
small group of patients with adult-onset (AO) GHD
(nZ8). The starting dose used was 5 mg/kg per day, and
the mean final GH dose was 6.7G0.8 mg/kg per day.
This regimen was effective in improving and/or normal-
ising heart structure and performance, together with
lipid profile, body composition and bone density in AO
patients. Chihara et al. (36) studied the effects of
long-term GH replacement therapy in Japanese adults
with GHD in a multicentre, uncontrolled, open-labelwww.eje-online.orgstudy, which followed on from a previous randomised,
double-blind, placebo-controlled trial, in which patients
received either GH replacement therapy (GH–GH group,
nZ35) or placebo (placebo–GH group, nZ36). In the
open-label study, patients received GH for 48 weeks.
Treatment was started at a dose of 0.003 mg/kg per day
for the first 8 weeks, after which the dose was adjusted
to maintain patients’ serum IGF1 levels within the
reference range adjusted for age and gender. Overall,
long-term, individualised GH administration based on
IGF1 levels was well tolerated and effective. Treatment
with GH maintained the improvements in body
composition and lipid profiles in the patients previously
treated in the double-blind study (GH–GH group) and
improved these parameters in previously untreated
patients (placebo–GH group). Compared with the
FD titration regimen of the preceding double-blind
comparative phase, the dosing methodology used in the
extended study allowed lower GH dose increases, and
the incidences of oedema and cases of high levels of
IGF1 were lower.Timing and frequency of GH
administration
Some studies have explored the frequency and timing of
GH injections for the optimal AGHD treatment schedule.
Regimens employing three injections per week have
been shown to improve and/or normalise heart
structure and performance, together with lipid profile,
body composition, and bone metabolism and structure
(23, 34). In a randomised, prospective, controlled study
comparing daily vs tiw injections (37), the tiw injection
regimen was effective in normalising IGF1 levels and
improving lipid profile, body composition, bone metab-
olism and bone density; this effect was comparable with
that observed in patients treated with daily injections,
with few side effects and good compliance. Given that
the benefits of GH therapy have been observed to reverse
after 12 months off treatment (34), and that lifelong
therapy might be necessary, compliance is an important
issue in the treatment of AGHD. Indeed, current
guidelines (5) suggest that, for patients with compliance
issues, clinicians may consider administering injections
on alternate days or tiw using the same total weekly
dosage.
Jørgensen et al. (38) investigated whether the timing
of GH administration in patients with GHD had any
impact on its action. It was concluded that the
modulatory effects of GH replacement therapy were
substantially influenced by the time of its adminis-
tration; evening injections were more successful than
morning injections in normalising the circadian
patterns of hormones and metabolites crucial for
intermediary metabolism.
Evidence suggests that there is no clinically rele-
vant difference between continuous vs intermittent
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may play more of a role in the selected regimen in
this context.
In the last few years, new sustained-release GH
preparations have been developed (both for paediatric
and adult populations) in order to increase patients’
adherence to treatment (injections administered once
per week) while avoiding overtreatment (42). Long-term
treatment with a weekly sustained-release GH prep-
aration over both 26 and 52 weeks in adults with GHD
demonstrated a reduction in fat mass with a favourable
side-effect profile, confirming the potential value and
safety of such agents for long-term GH replacement.Factors affecting dose responsiveness
Treatment guidelines recognise the need to adjust the
GH dose for certain categories of patients to reflect
variations in physiological GH secretion. GH secretion is
greater in younger individuals than older ones, and in
women than men, and secretion is reduced in obesity
(7, 20). Therefore, there are differences in the
recommended starting doses for different patients in
the GRS guidelines (7): 0.2 and 0.3 mg/day in young
men and women respectively, and 0.1 mg/day in older
individuals.
AACE guidelines (5) also take into account factors that
may affect dosing and recommend dose changes in the
following circumstances: increase the dose for young
patients, regardless of onset type, with the addition of
oral oestrogen or change from transdermal to oral
oestrogen and decrease the dose for elderly patients, with
discontinuation of oral oestrogen, change from oral to
transdermal oestrogen or the addition of testosterone.Gender
During childhood, there are no differences between boys
and girls with respect to GH production. However, at
pubertal and adult ages, differences can be found. GH
production in healthy women of reproductive age is
about twofold higher than in men, but IGF1 levels are
similar, suggesting a lower responsiveness to GH in
women (43, 44). This gender difference is closely related
to oestrogen secretion and is possibly influenced by
serum testosterone as well. In contrast to healthy men
and women, IGF1 levels in adults with GHD are lower in
women than in men, and there is a gender difference in
GH requirement, with women needing higher doses and
a longer duration to achieve the same clinical effects
and IGF1 levels. The AACE guidelines state that women
require higher initiation and maintenance doses than
their male counterparts to achieve an equivalent
clinical and biochemical response (5).
In clinical studies, gender differences in the doses
required to normalise IGF1 levels have indeed been
noted in subgroup analyses, with females receiving ahigher GH replacement dose than males in some studies
(28, 35), although some have found no significant
differences in GH dose needed between men and women
(22, 45) when dose adjustments are made for baseline
factors such as age, BMI, and dose of GH itself (46).
Differences in the response to GH, as reflected by
changes in body composition, have been observed, with
several studies demonstrating greater effects in males
than in females. In the 6-month, low-dose GH
replacement study of Mukherjee et al. (45), the
percentage changes in lean body mass and fat mass
were significantly greater in males. Likewise, Bell et al.
(47) reported that males responded significantly to
treatment with GH in terms of changes in waist
circumference, trunk fat, conicity index and somato-
type, whereas in females, the only significant change
was in trunk fat, and Chihara et al. (36) reported
changes in mean lean body mass and mean body fat
mass at week 48 of C4.1G4.5 and K2.4G10.5%,
respectively, in females compared with C5.0G6.7 and
K8.9G11.8%, respectively, in males. Mixed results
were found by Hoffman et al. (29), who compared
outcomes for FD and ID regimens and found that the
decrease in fat mass was greater with the FD than the ID
regimen for men but not for women, and the change in
waist circumference was greater with the FD than the
ID regimen for women but not for men.Age
Current age and age of GHD onset are also factors that
may influence dose responsiveness. The doses used
during adolescence have typically been intermediate
doses between the paediatric doses required during the
growth years and the adult dose (7).
As the sensitivity to side effects of exogenous GH is
greater in elderly patients with GHD, AACE guidelines
advise that the starting dose, size of dose adjustments
and target serum IGF1 levels should be reduced when
GH replacement is considered in elderly patients (5, 7).
GRS guidelines state that in elderly patients with GHD,
treatment can be achieved with lower doses, concordant
with the observed physiological decrease in GH
secretion (7).
Differences in dose requirements and responses have
been observed in patients with AO GHD and CO GHD. In
the study by Chihara et al. (48), individualised GH
dosing resulted in a lower mean dose for patients with
AO compared with CO GHD (0.032G0.019 vs 0.061
G0.023 mg/kg per week). Dosing patterns in the two
groups were paralleled by the changes in IGF1 and
IGFBP3. Similarly, Murray et al. (35) noted that low-
dose individualised GH replacement, aimed at normal-
isation of serum IGF1 levels, was associated with a
significantly greater mean dose for CO than AO patients
at 12 months (0.45G0.18 vs 0.32G0.16 mg/day
respectively; PZ0.004) and at 24 months (0.53
G0.24 vs 0.33G0.20 mg/day; PZ0.024). Differenceswww.eje-online.org
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subgroups (AO patients had a more adverse lipid profile
at baseline) and also in the response of serum lipids to
GH replacement (changes in TC, LDL-C, and the
TC/HDL-C ratio were greater in AO patients) were
noted. A difference in the response to GH therapy in
patients with AO and CO GHD was also observed in a
later study by the same group (36), in which mean lean
body mass was increased by 6.2G6.8% in CO patients
and by 3.0G4.4% in AO patients after 48 weeks of
replacement. The authors suggested that this difference
probably reflected the fact that CO patients had lower
mean IGF1 levels at baseline and received higher
average doses of GH.
Current guidelines recommend that patients with CO
GHD should be retested after final height is achieved and
therapy discontinued for at least 1 month to ascertain
their GH status before considering restarting therapy
(4, 5). However, guidelines for downward dose titration
from a childhood to an adult dose are still lacking. Based
on the age-related reduction in the spontaneous rate of
GH production from puberty to young adulthood (49),
one could hypothesise that progressive titration of GH
dose during the transition phase to mimic physiological
changes would lead to a dose reduction ofw50% in 2–4
years. This progressive reduction could lead to attain-
ment of the appropriate dose for replacement in a young
adult in another 4 years (the time at approximately
which peak bone mass is physiologically obtained (50)).
In the transition phase, it is important to identify safe
regimens that can maximise linear growth potential
and final adult height; it is also important to investigate
the impact of age-adjusted regimens on carbohydrate
and lipid metabolism, bone accretion, attainment of
peak bone mass, body composition, behaviour, psycho-
sexual function, and QoL. Once again, it has to be
recommended that side effects are carefully monitored,
although they are unlikely to occur if the replacement
GH dose is appropriate.Obesity
Decreased basal and stimulated GH and basal IGF1
levels and increased responsiveness to GH treatment are
frequently reported in obesity. The role of obesity in
affecting hepatic IGF1 generation in response to GH was
explored by Yuen et al. (51) in a cohort of severely
GH-deficient non-obese and obese adults treated with a
fixed low GH dose (0.2 mg/day). Results demonstrated a
larger increment and decreased individual variability of
IGF1 to the low GH replacement dose in obese compared
with non-obese adults with severe GHD. A positive
association of IGF1 increment with baseline BMI
suggested that the increased hepatic responsiveness to
GH stimulation was more dependent on the degree of
obesity rather than the GHD itself. The authors
cautioned that the increased variability of IGF1 in non-
obese adults with severe GHD questions the reliabilitywww.eje-online.orgof interpreting an isolated single measurement of serum
IGF1 in guiding dose adjustments.
Current guidelines give special consideration to
patients who are obese, in stating that initiating and
maintaining GH therapy using low doses (0.1–0.2 mg/
day) may be more appropriate in GH-deficient patients
with concurrent diabetes or obesity, and in those with
previous gestational and family history of diabetes so as
not to increase blood glucose levels. Mild and often
transient changes in glucose metabolism have been
demonstrated to be associated with GH replacement
therapy in adults with GHD when compared with
untreated adults with GHD (52).
Adult patients with Prader–Willi syndrome should
be considered on an individual basis, due to the
coexistence of obesity with a variable degree of GHD
severity in a large majority of cases (53).Interactions with other therapies
Given the interaction of GH with other pituitary
hormone axes, it is advised that dose adjustments may
be needed for those on more than one type of
replacement therapy (5, 7, 44).
Studies on the interactions between sex steroid
replacement and GH action have shown that oestrogen,
administered orally, impairs GH action, leading to
higher GH dose requirements (7, 44). In addition, the
suppression of hepatic IGF1 generation by oral oestro-
gen (20) means that it is preferable for oestrogen to be
replaced by a non-oral route, as the GH requirements
will be reduced (7).
In patients with central adrenal failure, initiation of
GH treatment may require an increase in hydrocorti-
sone dose (7). Furthermore, by accelerating the
peripheral metabolism of cortisol, GH therapy may
precipitate adrenal insufficiency in susceptible hypopi-
tuitary patients (44).
Porretti et al. (54) reported that low doses of GH may
unmask the presence of a mild central hypothyroid state
or might even worsen a pre-existing central hypothyr-
oidism, making it necessary to adjust replacement
thyroid hormone doses in patients receiving thyroxine
replacement.Baseline disease characteristics
The degree of severity at the start of therapy has also
been found to affect responsiveness to GH therapy in
adults, with greater responses being observed in those
with a more severe disease profile. Murray et al. (35)
demonstrated that the greatest improvements in the
serum lipid values after 2 years of GH therapy occurred
in those patients with the highest levels at baseline.
Female patients, AO patients and patients with multiple
pituitary hormone deficits had a significantly more
adverse lipid profile at baseline than male patients, CO
patients and patients with isolated GHD, respectively,
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subgroups. In addition, a study that selected severely
GH-deficient adult patients with poor QoL and replaced
GH using a low-dose titration regimen aimed at normal-
ising the IGF1 level found that the observed improvement
in QoL was proportional to the degree of impairment
(QoL score) before commencing therapy (24).
The influence of age, sex, and obesity on GH
requirements has been attributed to differences in
baseline serum IGF1 levels. From a multiple linear
regression analysis, age, gender, weight, and age at onset
of GHD had no independent effect on GH requirement,
and the observed effect of these variables on the final GH
dose was accounted for by the lower pre-treatment IGF1
S.D. in young, female and CO patients compared with
older, male and AO patients respectively (55).Treatment monitoring: assessments
before and/or during treatment
Treatment guidelines recommend regular assessment
of a number of efficacy measurements and safety
variables known to be modulated by GH to monitor the
effects of treatment. Unlike in paediatric GHD, where
the outcome of treatment is clearly visible (i.e. growth),
there is no one single optimal marker used to monitor
efficacy in AGHD. As each efficacy measurement is only a
crude marker of GH status, the use of several markers is
thought to extend the dimension of normalisation in the
individual and therefore improve safety during long-
term replacement (28). In addition, there is no fixed
treatment target to attain; studies often assess efficacy
by comparing parameters with pre-treatment values and
look for a shift in the right direction, or by comparing
values against those for a control group (usually healthy
subjects matched for sex, age, and BMI), with pre-
treatment values being significantly lower than in
controls and normalising following GH therapy.
As discussed above, serum IGF1 is the best available
marker to guide therapy, and most endocrinologists
recommend slowly increasing GH until a target in the
normal range is reached with reduction instigated if
overdosage is apparent. In the event of dose adjustment,
it is advised that assessment should be performed no
sooner than 6 weeks after the dose change. After these
initial adjustments, the frequency of IGF1 measure-
ments can usually be decreased to once or twice per
year (56). The use of other biochemical parameters as
treatment targets, such as free IGF1, IGFBP3, or acid
labile subunit, is not perceived to be of value, as the
general consensus is that these will not add to the
monitoring power of IGF1 analysis alone (56).
Current guidelines recommend that, once mainten-
ance doses are achieved, objective parameters such as
body composition should be used to monitor the
response. Body composition can be assessed by
anthropometric measurements and also dual-energyX-ray absorptiometry (DXA), which provides a measure
of lean mass and fat mass (and is also a tool for assessing
bone density).
In recognition of the increased risk of cardiovascular
morbidity and mortality in hypopituitary patients, a
number of cardiovascular risk markers may be
considered for yearly monitoring, including fasting
lipid profile, diastolic blood pressure, and electrocardio-
gram results. Echo-Doppler assessment of arterial intima
media thickness and heart morphology and function
may shed further light. Fasting glucose levels should also
be monitored yearly because of increased prevalence of
obesity and the potential for GH replacement to affect
insulin sensitivity in these patients (7).
Measurement of bone mineral content and density
before starting therapy is also recommended due to the
increased risk of patients with AGHD developing
osteopaenia and osteoporosis. If the initial bone DXA
scan is abnormal, repeated scans are recommended at
2–3-yearly intervals to assess the need for additional
bone-treatment modalities (5).
Adults with GHD have diminished QoL, and therefore,
it is recommended that a specific questionnaire is
administered before the start of treatment and
evaluated annually thereafter to ascertain whether
there is a change or sustained effect of therapy on QoL
(5). Attention to parameters, such as energy level,
partner satisfaction, sick days, and vitality, is thought to
be of value in monitoring treatment response. Unlike
other outcome measures discussed above, QoL is a
subjective measure of treatment response. Whether
alterations in lean body mass and/or total body water
homoeostasis contribute to the perceived QoL deficit
in GHD and whether favourable changes in these
parameters translate into clinically meaningful
improvements in QoL was explored by Mukherjee et al.
(45). It was concluded that improved QoL was not
explained by favourable changes in body composition.
The responses to GH therapy described above may
only be observed after long-term therapy. As 6–8
months may be required to define a satisfactory dose
of GH, with body changes following, it has been
recommended that parameters such as body compo-
sition and lipid profile may be best assessed semi-
annually/annually (20).
The limitations of short-term placebo-controlled trials
in a condition in which treatment responses may occur
gradually were recognised by Widdowson & Gibney
(57). In a meta-analysis to determine whether evidence
exists to support a beneficial effect of GH replacement on
strength, it was found that, although long-term open-
label studies provide compelling evidence that GH
replacement in GHD improves muscle strength over a
period of 1–10 years, the meta-analysis of placebo-
controlled trials failed to confirm this. The authors
concluded that this was almost certainly due to the
short-term nature of such studies; unless carried out for
a duration exceeding 12 months (which is an unlikelywww.eje-online.org
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‘gold standard’ randomised controlled trial was unlikely
to provide appropriate answers to the question of
whether, in GHD, there is an improvement in muscle
strength with GH replacement.Closing remarks
The aim of this review was to assess and present the
evidence supporting the current guidelines on starting
doses of GH for use in adult patients. This review also
summarises the benefits, adverse events, and factors
affecting dose responsiveness as derived from the
scientific literature. Although the guidelines published
most recently also discuss the evidence supporting
treatment regimen recommendations to some extent
(1, 3, 4, 5, 7), the current review expands on the
information presented in the guidelines and includes a
fuller discussion of the findings. Guidelines published by
the Endocrine Society consider the strength of each
recommendation and the quality of the supporting
evidence (4). The recommendation that ‘GH-dosing
regimens be individualised rather than weight-based
and start with low doses and be titrated according
to clinical response, side effects and IGF1 levels’ is
considered a ‘strong’ recommendation, was developed
using high-quality evidence.
The published data discussed here also support the
use of low GH dosing regimens in AGHD. The range of
doses defined as ‘low dose’ in the studies discussed here
(w1–4 mg/week, based on studies in which dose was
expressed in mg/IU per day per week) is in accordance
with those recommended in current guidelines
(0.7–3.5 mg/week) (4, 5, 7) and encompasses the dose
range recommended by product labels (w1.1–2.1 mg/
week) (9, 10, 11, 12, 13, 14, 15, 16, 17, 18). Low GH
doses here are associated with few adverse effects, while
the first proposed doses to treat AGHD were associated
with a greater occurrence of adverse events.
The literature included here was selected using a
systematic approach but was not a fully systematic
review, and we acknowledge that the literature search
and selection process may have limited the scope of the
review. However, the data from the literature reported
here are the most frequently cited on the subject and
provided conclusions similar to the recent consensus
guidelines.
Aside from being associated with good efficacy and
safety outcomes, there are other potential benefits of
such regimens. Long-term adherence to treatment is a
potential issue associated with GH therapy, especially if
the patient does not feel any obvious beneficial effect. It
is estimated that 20–30% of patients will discontinue
treatment, permanently or for extended periods, making
objective evaluation of the long-term therapeutic effects
difficult (25). Indeed, it has been demonstrated that the
beneficial effects of GH, particularly on bodywww.eje-online.orgcomposition, disappear quite rapidly after stopping
treatment (58, 59). Alternate day or tiw dosing in
adults has been shown to be as effective as daily dosing
(37). As the frequency of injections is thought to be one
of the factors contributing to non-adherence to GH
therapy (60), a lower frequency dosing schedule is likely
to be less burdensome to patients and may have the
potential to improve adherence to treatment. New
sustained-release weekly GH preparations could
improve therapeutic adherence if their safety and
efficacy were similar to that of daily dosing (42).
Chronic, lifelong GH therapy may be associated
with considerable costs for both patients and society.
Low-dose schedules may potentially have pharmaco-
economic benefits, as lower doses could lead to
reductions in healthcare costs. However, there are few
data on pharmacoeconomic evaluations in GHD, and
more studies are needed in this area (61). Moreover, low
doses show similar, or even long-term greater, clinical
effect than higher doses, with reduced likelihood of
adverse effects. Given that the occurrence of adverse
effects may require out-patient visits or hospital
admission, or other treatments, and result in dimin-
ished productivity, the cost implications of inappropriate
dosing are also an important consideration (4, 5, 7, 56).Declaration of interest
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